Navigating the Evidence: Pathways for New and Emerging BCMA Therapies

Estimated Time
0.50 hour

Release Date
Feb 02, 2023

Expiration Date
Feb 08, 2024

Activity Description
Despite treatment advances, most patients with multiple myeloma will progress after administration to the standard of care regimens, including proteasome inhibitors, immunomodulatory agents, and chemotherapy. Therefore, it is important for the continual development of novel and effective therapies, especially for underserved communities. Agents targeting B-cell maturation antigen (BCMA) have shown substantial therapeutic responses. Join us in the 2nd episode of the 3-part Med Table Talk® on Navigating the Evidence: Pathways for New and Emerging BCMA Therapies as our expert faculty discuss the safety and efficacy of the emerging BCMA agents. In addition, don’t miss out on the featured conversation with Dr. Saad Usmani, MD, as he discusses practical strategies to improve diversity in clinical trial enrollment.


Accreditation and Disclosure Information

Target Audience
This activity is intended for hematologic oncologists, physician associates, nurses, and pharmacists who provide care for individuals with Relapsed or Refractory Multiple Myeloma (RRMM).

Educational Objectives
After completing this activity, the participant should be better able to:

  • Differentiate the mechanisms of drug resistance/loss of response for emerging BCMA-targeted approaches
  • Evaluate the clinical implications of emerging safety and efficacy data for novel BCMA-directed therapies
  • Create strategies to improve diversity in clinical trial enrollment and access to care

Program Agenda

  • Welcome
  • Drug resistance mechanisms using standard first-line regimens
  • Efficacy and safety of emerging BCMA-directed therapies
  • Strategies to promote timely initiation of care for underrepresented communicates, increase clinical trial enrollment, and advocate for access to care
  • Review of key points
  • Wrap-up

Accreditation, Support and Credit

Joint Accreditation with Commendation logo

In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 0.5 contact hour and 0.5 contact hour in the area of pharmacology.

Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 0.5 contact hour (0.05 CEU) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-007-H01-P
Type of Activity: Knowledge

AAPA Credit Designation Statement

Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credit. Approval is valid until February 8, 2024. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement


This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. 


Support Statement
This activity is supported by educational grants from Pfizer, Bristol Myers Squibb, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Disclosure & Conflict of Interest Policy
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.

Faculty Disclosures
Paula Rodríguez Otero, MD, PhD

Consultant in Hematology
Clínica Universidad de Navarra
Pamplona, Spain

Paula Rodríguez Otero, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: AbbVie, Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen, Pfizer, Sanofi
Speakers’ Bureau: Amgen, Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen, Regeneron, Sanofi

Adrienne A. Phillips, MD, MPH

Associate Professor of Clinical Medicine
Associate Fellowship Program Director
Department of Medicine
Division of Hematology & Medical Oncology
Weill Cornell Medicine
New York, NY

Adrienne A. Phillips, MD, MPH, has no relevant financial relationship(s) with ineligible companies to disclose for this educational activity.

Melody Smith, MD, MS

Assistant Professor of Medicine
Stanford University, Department of Medicine
Division of Blood & Marrow Transplantation and Cellular Therapy
Stanford, CA

Melody Smith, MD, MS, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: Bristol Myers Squibb

Saad Z. Usmani, MD, MBA, FACP

Chief of Myeloma Service
Memorial Sloan Kettering Cancer Center
Attending Physician, Myeloma, Cellular Therapy and Adult BMT Services
New York, NY

Saad Z. Usmani, MD, MBA, FACP, has a financial interest/relationship or affiliation in the form of:
Research Grant: Amgen, Array Biopharma, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda
Advisory Board/Consultant: Abbvie, Amgen, Bristol Myers Squibb, Celgene, EdoPharma, Genentech, Gilead, GlaxoSmithKline, Janssen, Oncopeptides, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, TeneoBio

All of the relevant financial relationships of individuals for this activity have been mitigated.

Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute, Inc.

For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

If you have questions regarding your certificate, please contact Mary Vu via email at

For Pharmacists, MLI will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website:

About This Activity
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.

Copyright © 2023 Medical Learning Institute, Inc. All Rights Reserved.